Business Context and Reporting Period
This Form 8-K is filed by BioZone Pharmaceuticals, Inc. (not Cocrystal Pharma, Inc.) for the reporting period of September 22, 2011. The company is incorporated in Nevada and is based in Englewood Cliffs, NJ. The filing discloses the creation of a direct financial obligation and the unregistered sale of equity securities.
Key Financial Metrics
The filing details a specific financing transaction rather than periodic financial performance metrics such as revenue or operating cash flow.
- Debt Issued: $500,000 principal amount convertible promissory note.
- Interest Rate: 10% per annum.
- Maturity Date: March 22, 2012, or the closing date of a planned PIPE Offering, whichever is earlier.
- Target Financing: The company intends to close a Private Investment in Public Equity (PIPE) Offering yielding at least $8,000,000 within 120 days of the note issuance.
Material Changes
The primary material change is the issuance of the $500,000 convertible note and associated warrant to an accredited investor on September 22, 2011. This transaction was executed under Section 4(2) of the Securities Act and Rule 506. The note includes a provision allowing the holder to convert the principal and accrued interest into PIPE securities at 70% of the PIPE share price upon the consummation of the offering.
Outlook, Risks, and Unusual Items
Outlook: Management intends to complete a PIPE Offering of at least $8,000,000 within 120 days. The success of this offering is critical as it determines the maturity date of the current note and the conversion terms.
Terms and Risks:
- Warrant Terms: The accompanying warrant is immediately exercisable for five years. The exercise price is the lower of $1.80 or 120% of the PIPE share price, with a "ratchet" anti-dilution adjustment for one year.
- Conversion Risk: If the PIPE Offering closes, the note holder may elect to convert debt into equity at a significant discount (70% of the offering price) or demand cash repayment.
- Liquidity: The filing does not provide current cash balances or liquidity metrics, only the terms of the new debt instrument.
Investor Verification Checklist
- Verify the company name discrepancy: The filing is for BioZone Pharmaceuticals, Inc., not Cocrystal Pharma, Inc.
- Confirm the status of the planned $8,000,000 PIPE Offering and whether it has been closed within the 120-day window.
- Review the full text of the Securities Purchase Agreement and Warrant (Exhibits 10.1 and 10.3) for detailed anti-dilution mechanics.
- Assess the company's current cash position to determine its ability to repay the $500,000 note if the PIPE Offering fails to close.